Effects of the Consumption of California Walnuts on Cardiovascular Health

November 1, 2013 updated by: University of California, Davis

Effects of California Walnuts on Vascular Function and Immune Health in Postmenopausal Women

The purpose of this study is to determine the effects of the 4-week consumption of California walnuts on vascular function and immune health in postmenopausal women of ages 50-70.

Primary outcome measures:

  • vascular endothelial function
  • platelet reactivity
  • indoleamine 2, 3-deoxygenase (IDO)

Secondary outcome measures:

  • relationship of walnut intake to lipoprotein, fatty acids and oxylipins

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Cardiovascular disease is the leading cause of morbidity and mortality in the United States. The initiation and progression of atherosclerotic vascular disease is multifactoral in nature, and includes endothelial dysfunction, triggered by chronic inflammation. The consumption of foods rich in flavonoids and other phytochemicals has been inversely associated with cardiovascular disease risk in several epidemiological studies.

Aging is physiologically associated with a variable decline in several features of the immune function. In fact, immunosenescence, or aging of the immune system, is characterized by a reduced ability to fight infection and mount an adequate immune response once a novel infection is introduced. Both the innate and acquired immune systems can be affected with immune specific cells, cell signaling, cytokine production, and cell surface marker expression being all subject to age-related changes. The immune system cells within the digestive tract are an accessible and ideal target to stimulate immunity and diet-based nutritional interventions represent a non-invasive, relatively low-cost, and effective method of stimulating the immune function thus ultimately improving the antibody production in subjects at risk for immunosenescence. This is also based on the significant and dynamic interaction between luminal nutrients and the overall immune function. The study of nutritional influences on the immune system represents an area of growing interest to nutritionists, food scientists and immunologists. In general terms, dietary components have the potential to be an accessible and effective immune stimulant given the antigen presenting capacity of the intestine.

Due to their age and menopausal status, postmenopausal women are at a greater risk population for developing CVD. Males tend to show greater rates of CVD than pre-menopausal women, while women following menopause show an increase in CVD development. This increase in CVD for postmenopausal women is associated with endothelial dysfunction that becomes worse with age.

Recent studies have reported that consumption of walnuts is associated with beneficial effects in prevention of chronic diseases, such as cardiovascular disease (CVD), by favorably altering human serum profiles (i.e. decrease in LDL cholesterol and triglycerides and increase in HDL cholesterol and apolipoprotein A1). It has been shown that the consumption of walnuts, which mainly contain α-linolenic acid (ALA), L-arginine, and polyphenols, can beneficially alter vascular function and reduce inflammatory biomarkers. For example, Dr. Ros and his colleagues demonstrated that the addition of walnuts to a high-fat meal could improve endothelial function. This favorable influence on vasoactivity has been attributed to the antioxidant and anti-inflammatory properties of certain biofactors found in the walnuts.

In this study, we will focus on defining the potential role of California walnuts and its effects on vascular health and immune function. We will determine whether short term (4 week) consumption of California walnuts, particularly rich in ALA, L-arginine and polyphenols will improve endothelial function, platelet reactivity and immune function in an at-risk population of postmenopausal women 55-70 years of age.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Davis, California, United States, 95616
        • Ragle Human Nutrition Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • 50 to 70 years of age
  • Lack of menses in the last year and FSH 23-116.3 mlU/mL
  • Subject is willing and able to comply with the study protocols.
  • Subject is willing to consume California walnuts daily for four weeks.
  • BMI 18.5-34.9 kg/m2
  • Weight ≥ 110 pounds

Exclusion Criteria:

  • BMI ≥ 35 kg/m2
  • Self reported use of anticoagulation agents including NSAIDs
  • Self reported use of oral cortisone or other immunosuppressive agents,
  • Self reported underlying neoplasia or immunological disease,
  • Dislike of walnuts
  • Food faddists or those taking a non-traditional diet
  • Self reported physical activity restricted or reduced due to chronic health conditions
  • Self reported diabetes
  • Blood pressure ≥ 160/90 mm Hg
  • PFA-100 readings 10 % outside of normal reference range (normal reference range for ADP-Collagen: 71-118 sec; Epinephrine-Collagen: 94-193 sec).
  • Self reported renal or liver disease
  • Self reported heart disease, which includes cardiovascular events and Stroke
  • Self reported Cushing's syndrome
  • Self reported chronic/routine high intensity exercise
  • Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
  • Abnormal Liver, CBC or Chemistry panels (laboratory values outside the reference range) if determined to be clinically significant by Dr. M. Eric Gershwin.
  • Self reported cancer within past 5 years
  • Self reported history of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated with antidepressants within the last 1 year.
  • Self reported use of MAOI inhibitor within the last 1 year (e.g. phenelzine (Nardil), tranylcypromine (Parnate), etc)
  • Self reported malabsorption
  • Self reported anxiety medications
  • Self reported routine use of prescription drugs or over-the counter medications, which may potentially modulate the outcome of this study; including antibiotics, aspirin and aspirin-containing formulations, COX-2 inhibitors, antihistamines, corticosteroids, hypertensive medications, such as ACE-inhibitors and beta-blockers.
  • Asthma (can be worsened by mild to moderate food allergies).
  • Indications of substance or alcohol abuse within the last 3 years
  • Use of multi-vitamin and mineral other than a general formula of vitamins and minerals that meet the RDA
  • Use of herbal or plant-based supplements; omega-3 fatty acids, and fish oils in the past 3-6 months, and unwilling to discontinue use while participating in the study.
  • Self reported nut allergies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 5 g of walnuts
The consumption of assigned walnuts once a day during 4 weeks
EXPERIMENTAL: 40 g of walnuts
The consumption of assigned walnuts once a day during 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endothelial function
Time Frame: 0 and 4 hours, 4 weeks after
Endothelial function is assessed by using peripheral arterial tonometry (PAT).
0 and 4 hours, 4 weeks after

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Robert M Hackman, Ph. D, University of California, Davis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (ACTUAL)

June 1, 2012

Study Completion (ACTUAL)

June 1, 2012

Study Registration Dates

First Submitted

October 28, 2010

First Submitted That Met QC Criteria

November 3, 2010

First Posted (ESTIMATE)

November 5, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

November 3, 2013

Last Update Submitted That Met QC Criteria

November 1, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 200917609-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Immune Function

Clinical Trials on Walnuts

Subscribe